Figure 4. Fap1-inhibition decreases tumor growth in a murine xenograft model of colon cancer.

SW620 cells were injected in the flanks of athymic Nude mice and tumor volume was determined biweekly. Some mice were injected daily with Fap1-blocking SLV peptide and others with VLS control peptide (n=12 per cohort). Other mice were treated weekly with oxaliplatin (day 0, 7 and 14) and daily with Fap1 blocking SLV peptide or VLS control peptide (n=12 per cohort). (A) Treatment with SLV peptide decreases the rate of tumor growth with or without oxaliplatin. Significant differences in tumor size at the same time point are indicated by ^* or ^** (p<0.01, n=12). (B) Treatment with oxaliplatin or SLV peptide increases survival, and the combination increases survival more than either alone. The percent of surviving mice during SLV versus VLS peptide treatment over time was determined (Χ²=5.52, p=0.02, n=12 for comparison of mice treated with VLS vs SLV peptide, and Χ²=6.2, p=0.01, n=12 for comparison of mice treated with oxaliplatin with VLS versus SLV peptide).